Absence of Allotypic Variation in the Autoantigen for Thyroid Stimulating Autoantibodies

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 1983 May 1

PMID 6134598

Authors

A Knight

D D Adams

Affiliations

Soon will be listed here.

Abstract

The question of whether autoimmune reactions result from abnormality of the autoantigen or of the autoantibody is fundamental. When reaction of the thyroid stimulating autoantibodies (TSaab) of Graves' disease with their autoantigen is measured in the mouse bioassay which has a very sensitive dose-response curve this provides a favourable system for detecting any influence of allotypic variation in the autoantigen on the affinity of the corresponding autoantibodies. Seven high potency long acting thyroid stimulator (LATS) sera were tested for degree of neutralization by soluble extracts from nine thyroids, using the mouse bioassay to measure changes in LATS activity. The thyroid extracts differed in neutralizing potency and the LATS sera differed in susceptibility to neutralization, but these variations were consistent enough to enable ranking and there were no significant exceptions from especially strong or weak reactions between any individual thyroid extract and any individual LATS serum. Even autologous reactants had no greater or lesser affinity than homologous ones. Five LATS protector (LATSP) sera, tested against six thyroid extracts, including their own, again showed no evidence of allotypic variation in the autoantigen, nor did 55 LATSP sera tested with one of four thyroid extracts. Altogether we have looked at over 200 individual reactions between soluble thyroid antigen and thyroid stimulating autoantibody (LATS and LATSP). We have not found a single significant instance of any exceptionally strong or weak affinities, even with autologous antigen. The findings are in accord with Burnet's theory that autoimmune reactions are due to the emergence of forbidden clones of lymphocytes, reactive with normal self antigens.

References

Beall G, Solomon D . Inhibition of long-acting thyroid stimulator by thyroid particulate fractions. J Clin Invest. 1966; 45(4):552-61. PMC: 292729. DOI: 10.1172/JCI105369. View

Adams D, KENNEDY T . Occurrence in thyrotoxicosis of a gamma globulin which protects LATS from neutralization by an extract of thyroid gland. J Clin Endocrinol Metab. 1967; 27(2):173-7. DOI: 10.1210/jcem-27-2-173. View

Berumen F, Lobsenz I, UTIGER R . Neutralization of the long-acting thyroid stimulator by thyroid subcellular fractions. J Lab Clin Med. 1967; 70(4):640-9. View

BENHAMOU-GLYNN N, Roitt I, Doniach D . Studies on the antigen reacting with the thyroid-stimulating immunoglobulin (LATS) in thyrotoxicosis. Immunology. 1969; 16(2):187-204. PMC: 1409579. View

Adams D, KENNEDY T . Evidence to suggest that LATS protector stimulates the human thyroid gland. J Clin Endocrinol Metab. 1971; 33(1):47-51. DOI: 10.1210/jcem-33-1-47. View

SHISHIBA Y, Shimizu T, Yoshimura S, SHIZUME K . Direct evidence for human thyroidal stimulation by LATS-protector. J Clin Endocrinol Metab. 1973; 36(3):517-21. DOI: 10.1210/jcem-36-3-517. View

Dirmikis S, MUNRO D . Studies on the binding activity for the long-acting thyroid stimulator. J Endocrinol. 1973; 58(3):577-90. DOI: 10.1677/joe.0.0580577. View

Dirmikis S, MUNRO D . Comparative studies on the reduction of the response to the long-acting thyroid stimulator by soluble fractions from human, ovine, bovine and porcine thyroids. J Endocrinol. 1973; 59(3):579-92. DOI: 10.1677/joe.0.0590579. View

Smith B, Hall R . Thyroid-stimulating immunoglobulins in Graves' disease. Lancet. 1974; 2(7878):427-31. DOI: 10.1016/s0140-6736(74)91815-7. View

10.

Adams D, FASTIER F, HOWIE J, KENNEDY T, KILPATRICK J, Stewart R . Stimulation of the human thyroid by infusions of plasma containing LATS protector. J Clin Endocrinol Metab. 1974; 39(5):826-32. DOI: 10.1210/jcem-39-5-826. View

11.

Dirmikis S . Some factors affecting the detection of long-acting thyroid stimulator protector using the McKenzie bioassay. J Endocrinol. 1974; 63(3):427-38. DOI: 10.1677/joe.0.0630427. View

12.

Dirmikis S, MUNRO D . Placental transmission of thyroid-stimulating immunoglobulins. Br Med J. 1975; 2(5972):665-6. PMC: 1673547. DOI: 10.1136/bmj.2.5972.665. View

13.

Adams D, KENNEDY T, Stewart R . Evidence that mouse thyroid stimulator does not stimulate the human thyroid gland. Aust N Z J Med. 1976; 6(4):300-4. DOI: 10.1111/imj.1976.6.4.300. View

14.

Muggeo M, Ginsberg B, Roth J, Neville Jr D, De Meyts P, Kahn C . The insulin receptor in vertebrates is functionally more conserved during evolution than insulin itself. Endocrinology. 1979; 104(5):1393-402. DOI: 10.1210/endo-104-5-1393. View

15.

SHISHIBA Y, Takaishi M, Shimizu T . Inactivation of human thyroid stimulator by human thyroid extract. Endocrinol Jpn. 1979; 26(2):285-9. DOI: 10.1507/endocrj1954.26.285. View

16.

Kong Y, Rose N, Elrehewy M, Michaels R, Giraldo A, Accavitti M . Thyroid alloantigens in autoimmunity. Transplant Proc. 1980; 12(3 Suppl 1):129-34. View

17.

Karlsson F, Dahlberg P, Walinder O . Activation of membrane-bound adenylcyclase by thyroid stimulating antibodies. Acta Endocrinol (Copenh). 1981; 97(1):60-6. DOI: 10.1530/acta.0.0970060. View

18.

Knight A, Adams D . Autoantibodies with intrinsic biological activity. Horm Res. 1980; 13(2):69-80. DOI: 10.1159/000179273. View

19.

Gossage A, Byfield P, Copping S, HIMSWORTH R . A comparative study of the binding of Graves' immunoglobulins by the patients own and other thyroid membranes. Clin Endocrinol (Oxf). 1981; 14(3):301-10. DOI: 10.1111/j.1365-2265.1981.tb00199.x. View

20.

Hardisty C, Hanford L, Humphries H, MUNRO D . Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis. Clin Endocrinol (Oxf). 1981; 14(6):631-9. DOI: 10.1111/j.1365-2265.1981.tb02975.x. View